STEVE ASELAGE Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for STEVE ASELAGE.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of STEVE ASELAGE. STEVE ASELAGE is Director in BIOCRYST PHARMACEUTICALS INC ($BCRX) and EVP, Global Commercial Ops in CTI BIOPHARMA CORP ($CTIC) and in Acer Therapeutics Inc. ($OPXA) and Director in Acer Therapeutics Inc. ($OPXA) and Chief Executive Officer in Retrophin, Inc. ($RTRX) and Director in Retrophin, Inc. ($RTRX).
Latest Insider Trading Transactions of STEVE ASELAGE
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACER, BCRX, CTIC, RTRX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Option Exercise | M | 16.23 | 10,000 | 162,300 | 140,000 | |
| Apr 20 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Sell | S | 26.23 | 10,000 | 262,300 | 188,940 | 198.9 K to 188.9 K (-5.03 %) |
| Apr 20 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Buy | M | 16.23 | 10,000 | 162,300 | 198,940 | 188.9 K to 198.9 K (+5.29 %) |
| Mar 19 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Option Exercise | M | 16.23 | 10,000 | 162,300 | 150,000 | |
| Mar 19 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Sell | S | 27.56 | 7,727 | 212,956 | 188,940 | 196.7 K to 188.9 K (-3.93 %) |
| Mar 19 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Sell | S | 27.35 | 10,000 | 273,500 | 196,667 | 206.7 K to 196.7 K (-4.84 %) |
| Mar 19 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Buy | M | 16.23 | 10,000 | 162,300 | 206,667 | 196.7 K to 206.7 K (+5.08 %) |
| Mar 02 2021 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Grant | A | 10.78 | 927 | 9,993 | 31,496 | 30.6 K to 31.5 K (+3.03 %) |
| Mar 02 2021 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Grant | A | 10.78 | 927 | 9,993 | 31,496 | 30.6 K to 31.5 K (+3.03 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Option Exercise | M | 10.09 | 25,000 | 252,250 | 275,000 | |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Sell | S | 30.75 | 25,000 | 768,750 | 196,667 | 221.7 K to 196.7 K (-11.28 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Buy | M | 10.09 | 25,000 | 252,250 | 221,667 | 196.7 K to 221.7 K (+12.71 %) |
| Jan 20 2021 | ACER | Acer Therapeutics ... | ASELAGE STEVE | Director | Option Exercise | A | 3.85 | 15,000 | 57,750 | 15,000 | |
| Dec 16 2020 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Sell | S | 26.02 | 5,549 | 144,385 | 196,667 | 202.2 K to 196.7 K (-2.74 %) |
| Dec 02 2020 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Grant | A | 5.11 | 1,956 | 9,995 | 30,569 | 28.6 K to 30.6 K (+6.84 %) |
| Nov 06 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 23.00 | 20,625 | 474,375 | 213,107 | 233.7 K to 213.1 K (-8.82 %) |
| Nov 06 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 21.26 | 2,500 | 53,150 | 233,732 | 236.2 K to 233.7 K (-1.06 %) |
| Sep 02 2020 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Grant | A | 4.15 | 2,409 | 9,997 | 28,613 | 26.2 K to 28.6 K (+9.19 %) |
| Aug 06 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 19.68 | 2,500 | 49,200 | 236,232 | 238.7 K to 236.2 K (-1.05 %) |
| Jul 28 2020 | ACER | Acer Therapeutics ... | ASELAGE STEVE | Director | Buy | P | 3.50 | 45,000 | 157,500 | 63,905 | 18.9 K to 63.9 K (+238.03 %) |
| Jun 29 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 20.00 | 10,000 | 200,000 | 238,732 | 248.7 K to 238.7 K (-4.02 %) |
| May 19 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Option Exercise | A | 15.43 | 9,000 | 138,870 | 9,000 | |
| May 19 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Grant | A | 0.00 | 3,000 | 0 | 248,732 | 245.7 K to 248.7 K (+1.22 %) |
| May 14 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 15.09 | 3,062 | 46,206 | 245,732 | 248.8 K to 245.7 K (-1.23 %) |
| May 14 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 15.09 | 3,062 | 46,206 | 245,732 | 248.8 K to 245.7 K (-1.23 %) |
| May 14 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 16.41 | 4,063 | 66,674 | 248,794 | 252.9 K to 248.8 K (-1.61 %) |
| May 14 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 16.41 | 4,063 | 66,674 | 248,794 | 252.9 K to 248.8 K (-1.61 %) |
| May 14 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 17.16 | 1,000 | 17,160 | 252,857 | 253.9 K to 252.9 K (-0.39 %) |
| May 14 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 17.16 | 1,000 | 17,160 | 252,857 | 253.9 K to 252.9 K (-0.39 %) |
| May 14 2020 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Option Exercise | A | 5.41 | 40,000 | 216,400 | 40,000 | |
| May 06 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 15.88 | 2,500 | 39,700 | 253,857 | 256.4 K to 253.9 K (-0.98 %) |
| Mar 09 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 15.36 | 4,359 | 66,939 | 256,357 | 260.7 K to 256.4 K (-1.67 %) |
| Mar 09 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Grant | A | 0.00 | 12,250 | 0 | 260,716 | 248.5 K to 260.7 K (+4.93 %) |
| Mar 03 2020 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Grant | A | 3.00 | 1,666 | 4,998 | 25,092 | 23.4 K to 25.1 K (+7.11 %) |
| Feb 07 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 16.62 | 2,500 | 41,550 | 248,466 | 251 K to 248.5 K (-1.00 %) |
| Jan 03 2020 | ACER | Acer Therapeutics ... | ASELAGE STEVE | Director | Option Exercise | A | 3.79 | 9,000 | 34,110 | 9,000 | |
| Dec 03 2019 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Grant | A | 2.85 | 1,754 | 4,999 | 23,426 | 21.7 K to 23.4 K (+8.09 %) |
| Nov 29 2019 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 13.91 | 5,000 | 69,553 | 250,966 | 256 K to 251 K (-1.95 %) |
| Nov 29 2019 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 13.91 | 5,000 | 69,553 | 250,966 | 256 K to 251 K (-1.95 %) |
| Nov 18 2019 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Buy | P | 1.45 | 15,000 | 21,750 | 21,672 | 6.7 K to 21.7 K (+224.82 %) |
| Sep 04 2019 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Grant | A | 2.99 | 1,672 | 4,999 | 6,672 | 5 K to 6.7 K (+33.44 %) |
| Jul 05 2019 | ACER | Acer Therapeutics ... | ASELAGE STEVE | Director | Buy | P | 3.72 | 5,000 | 18,581 | 18,905 | 13.9 K to 18.9 K (+35.96 %) |
| May 24 2019 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Buy | P | 3.57 | 3,000 | 10,710 | 5,000 | 2 K to 5 K (+150.00 %) |
| May 16 2019 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 17.82 | 1,838 | 32,753 | 255,966 | 257.8 K to 256 K (-0.71 %) |
| May 16 2019 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 17.79 | 1,838 | 32,698 | 257,804 | 259.6 K to 257.8 K (-0.71 %) |
| May 10 2019 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Option Exercise | A | 17.94 | 8,000 | 143,520 | 8,000 | |
| May 10 2019 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Grant | A | 0.00 | 2,000 | 0 | 259,642 | 257.6 K to 259.6 K (+0.78 %) |
| Mar 14 2019 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Buy | P | 8.30 | 2,000 | 16,600 | 2,000 | 0 to 2 K |
| Feb 13 2019 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Sell | S | 21.50 | 1,065 | 22,898 | 257,642 | 258.7 K to 257.6 K (-0.41 %) |
| Feb 13 2019 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Sell | S | 21.38 | 1,065 | 22,770 | 258,707 | 259.8 K to 258.7 K (-0.41 %) |
| Feb 05 2019 | ACER | Acer Therapeutics ... | ASELAGE STEVE | Director | Option Exercise | A | 24.46 | 6,000 | 146,760 | 6,000 | |
| Feb 05 2019 | ACER | Acer Therapeutics ... | ASELAGE STEVE | Director | Option Exercise | A | 24.46 | 6,000 | 146,760 | 6,000 | |
| Jan 08 2019 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Option Exercise | A | 8.62 | 25,000 | 215,500 | 25,000 | |
| Dec 21 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Sell | S | 22.35 | 900 | 20,111 | 259,772 | 260.7 K to 259.8 K (-0.35 %) |
| Dec 21 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Sell | S | 21.69 | 5,288 | 114,718 | 260,672 | 266 K to 260.7 K (-1.99 %) |
| Dec 21 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Sell | S | 21.97 | 6,188 | 135,958 | 265,960 | 272.1 K to 266 K (-2.27 %) |
| Dec 20 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Grant | A | 0.00 | 20,625 | 0 | 272,148 | 251.5 K to 272.1 K (+8.20 %) |
| Dec 07 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Sell | S | 24.04 | 10 | 240 | 251,523 | 251.5 K to 251.5 K (0.00 %) |
| Dec 07 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Gift | G | 0.00 | 1,750 | 0 | 251,533 | 253.3 K to 251.5 K (-0.69 %) |
| Nov 16 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Sell | S | 24.75 | 1,086 | 26,880 | 253,283 | 254.4 K to 253.3 K (-0.43 %) |
| Nov 16 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Sell | S | 24.21 | 4,464 | 108,089 | 254,369 | 258.8 K to 254.4 K (-1.72 %) |
| Nov 16 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Sell | S | 24.58 | 600 | 14,745 | 258,833 | 259.4 K to 258.8 K (-0.23 %) |
| Nov 16 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Sell | S | 23.63 | 4,950 | 116,990 | 259,433 | 264.4 K to 259.4 K (-1.87 %) |
| Aug 31 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Option Exercise | M | 8.70 | 12,000 | 104,400 | 0 | |
| Aug 31 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Sell | S | 32.00 | 12,000 | 384,000 | 245,883 | 257.9 K to 245.9 K (-4.65 %) |
| Aug 31 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Buy | M | 8.70 | 12,000 | 104,400 | 257,883 | 245.9 K to 257.9 K (+4.88 %) |
| May 14 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Option Exercise | A | 0.00 | 24,500 | 0 | 24,500 | |
| May 14 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Option Exercise | A | 25.25 | 147,000 | 3,711,750 | 147,000 | |
| May 14 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Grant | A | 0.00 | 24,500 | 0 | 245,883 | 221.4 K to 245.9 K (+11.07 %) |
| Mar 08 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Option Exercise | M | 6.00 | 278 | 1,668 | 0 | |
| Mar 08 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Buy | M | 6.00 | 278 | 1,668 | 221,383 | 221.1 K to 221.4 K (+0.13 %) |
| Feb 12 2018 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Grant | A | 0.00 | 3,549 | 0 | 221,105 | 217.6 K to 221.1 K (+1.63 %) |
| Dec 27 2017 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Gift | G | 0.00 | 23,000 | 0 | 217,556 | 240.6 K to 217.6 K (-9.56 %) |
| Dec 27 2017 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Gift | G | 0.00 | 5,000 | 0 | 240,556 | 245.6 K to 240.6 K (-2.04 %) |
| Dec 18 2017 | OPXA | Acer Therapeutics ... | ASELAGE STEVE | Director | Buy | P | 12.00 | 2,000 | 24,000 | 13,905 | 11.9 K to 13.9 K (+16.80 %) |
| Oct 06 2017 | OPXA | Acer Therapeutics ... | ASELAGE STEVE | Option Exercise | A | 15.34 | 6,000 | 92,040 | 6,000 | ||
| Sep 21 2017 | OPXA | Acer Therapeutics ... | ASELAGE STEVE | Option Exercise | J | 2.55 | 21,000 | 53,550 | 21,000 | ||
| Sep 21 2017 | OPXA | Acer Therapeutics ... | ASELAGE STEVE | Buy | J | 0.00 | 11,905 | 0 | 11,905 | 0 to 11.9 K | |
| Jun 14 2017 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Sell | P | 17.85 | 5,000 | 89,250 | 245,556 | 250.6 K to 245.6 K (-2.00 %) |
| May 18 2017 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Option Exercise | A | 17.44 | 165,000 | 2,877,600 | 165,000 | |
| Nov 23 2016 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Sell | S | 21.30 | 3,200 | 68,160 | 240,556 | 243.8 K to 240.6 K (-1.31 %) |
| Nov 23 2016 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Sell | S | 21.00 | 5,000 | 105,000 | 243,756 | 248.8 K to 243.8 K (-2.01 %) |
| Nov 23 2016 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Gift | G | 0.00 | 57,000 | 0 | 248,756 | 305.8 K to 248.8 K (-18.64 %) |
| May 23 2016 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Option Exercise | A | 16.23 | 160,000 | 2,596,800 | 160,000 | |
| Jan 29 2016 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Gift | G | 0.00 | 3,000 | 0 | 305,756 | 308.8 K to 305.8 K (-0.97 %) |
| Nov 12 2015 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Sell | S | 18.72 | 30,000 | 561,600 | 308,756 | 338.8 K to 308.8 K (-8.86 %) |
| Nov 12 2015 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Sell | S | 18.77 | 30,000 | 563,100 | 338,756 | 368.8 K to 338.8 K (-8.14 %) |
| Sep 15 2015 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Gift | G | 0.00 | 3,000 | 0 | 368,756 | 371.8 K to 368.8 K (-0.81 %) |
| Jul 02 2015 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Chief Executive Off ... | Option Exercise | A | 32.49 | 150,000 | 4,873,500 | 150,000 | |
| Feb 20 2004 | CTIC | CTI BIOPHARMA CORP | ASELAGE STEVE | EVP, Global Commerc ... | Buy | P | 8.90 | 2,000 | 17,800 | 6,000 | 4 K to 6 K (+50.00 %) |
| Feb 20 2004 | CTIC | CTI BIOPHARMA CORP | ASELAGE STEVE | EVP, Global Commerc ... | Buy | P | 9.00 | 2,000 | 18,000 | 4,000 | 2 K to 4 K (+100.00 %) |
| Feb 20 2004 | CTIC | CTI BIOPHARMA CORP | ASELAGE STEVE | EVP, Global Commerc ... | Buy | P | 9.10 | 2,000 | 18,200 | 2,000 | 0 to 2 K |
Page: 1